Elevated expression of CMP-N-acetylneuraminate-β-galactosamide-α-2,3-sialyltransferase 2 (ST3GAL2), the enzyme catalyzing the last step of SSEA4 synthesis, is associated with poor prognosis in breast cancers treated with chemotherapy. This evidence concerns the gene ST3GAL2 and breast carcinoma.